Patents Assigned to Hoechst Marion Roussel
  • Patent number: 7122669
    Abstract: Derivatives of purine having anti-proliferative properties and in particular, derivatives of purine endowed with an inhibitory effect vis-a-vis cycline-dependent kinase proteins i.e. abbreviated to “cdk”.
    Type: Grant
    Filed: May 18, 2000
    Date of Patent: October 17, 2006
    Assignee: Hoechst Marion Roussel
    Inventor: Jean-Luc Haesslein
  • Publication number: 20040229276
    Abstract: The present invention concerns a method for the screening of antimycotic substances wherein an essential gene from mycetes or a functionally similar mycete gene, or the corresponding encoded protein, is used as target and wherein the essential gene is selected from the group consisting in YML114c, YLR186w, YLR215c, YLR222c, YLR243w, YLR272c, YLR275w, YLR276c, YLR317w, YLR359w, YLR373c, YLR424w, YLR437c, YLR440c, YML023c, YML049c, YML077w, YML093w, YML127w, YMR032w, YMR093w, YMR131c, YMR185w, YMR212c, YMR213w, YMR218c, YMR281w, YMR288w, YMR290c, YMR211w, YMR049c, YMR134w, YDR196c, YDR299w, YDR365c, YDR396w, YDR407c, YDR416w, YDR449c, YDR472w, YDR499w, YDR141c, YDR324c, YDR325w, YDR398w, YDR246w, YDR236c, YDR361c, YDR367w, YDR339c, YDR413c, YDR429c, YDR468c, YDR489w, YDR527w, YDR288w, YDR201w, YDR434w, YDR181c, YDR531w, YPL126w, YPL093w, YPL063w, YPL024w, YPL020c, YPL012w, YPL007c, YPL233w, YPLI46c, YIL091c, YIL083c, YIL019w, YIL109c, YIL104c, YFL024c, YFR003c, YFR027w, YFR042w, YIR010w, YIR015w, YPR048w, YPR07
    Type: Application
    Filed: June 21, 2004
    Publication date: November 18, 2004
    Applicant: Hoechst Marion Roussel
    Inventors: Anita Diu-Hercend, Karl-Dieter Entian, Peter Koetter
  • Patent number: 6747148
    Abstract: Sulfonamide derivatives, their physiologically tolerable salts and their prodrugs according to the present invention are vitronectin receptor antagonists and inhibitors of cell adhesion, as well as inhibit bone resorption by osteoclasts. These derivatives, salts and prodrugs are pharmaceutically active compounds useful in the therapy and prophylaxis of diseases which are caused at least partially by an undesired extent of bone resorption, for example of osteoporosis. Processes for the preparation of the sulfonamide derivatives according to the present invention, the use of these derivatives as pharmaceutically active ingredients, and pharmaceutical preparations comprising these derivatives also are disclosed.
    Type: Grant
    Filed: October 9, 2001
    Date of Patent: June 8, 2004
    Assignees: Hoechst Marion Roussel Deutschland GmbH, Genentech, Inc.
    Inventors: Anuschirwan Peyman, David William Will, Jochen Knolle, Karlheinz Scheunemann, Denis Carniato, Jean-Francois Gourvest, Thomas R. Gadek, Robert McDowell, Sarah Catherine Bodary, Robert Andrew Cuthbertson
  • Publication number: 20040097544
    Abstract: The use of an inhibitor of the Na+/H+ exchanger for the production of a medicament for the treatment or prophylaxis of disorders of the central nervous system. Inhibitors of the Na+/H+ exchanger are outstandingly suitable for the production of a medicament for the treatment or prophylaxis of disorders of the central nervous system; derivatives of guanidine are particularly highly suitable; cariporide (HOE 642) is especially suitable.
    Type: Application
    Filed: April 28, 2003
    Publication date: May 20, 2004
    Applicant: Hoechst Marion Roussel Deutschland GMBH
    Inventors: Hans Jochen Lang, Klaus Wirth, Dieter Bingmann, Udo Bonnet, Martin Wiemann
  • Publication number: 20030203359
    Abstract: Polyamide-oligonucleotide derivatives of the formula
    Type: Application
    Filed: February 27, 2001
    Publication date: October 30, 2003
    Applicant: Hoechst Marion Roussel Deutschland GmbH
    Inventors: Eugen Uhlmann, Gerhard Breipohl
  • Publication number: 20030064514
    Abstract: The invention relates to a specific modified oligonucleotide complementary to a section of the human Hs-ras gene and mRNA, and its use to specifically regulate, modulate, or inhibit expression of the Ha-ras gene, and its use as a pharmaceutical for the treatment of conditions arising from the abnormal expression of the Ha-ras gene, in particular in combination with chemotherapy and radiotherapy.
    Type: Application
    Filed: February 17, 2000
    Publication date: April 3, 2003
    Applicant: HOECHST MARION ROUSSEL DEUTSCHLAND GmbH
    Inventors: EUGEN UHLMANN, ANUSCHIRWAN PEYMAN, DAVID WILLIAM WILL, ESTHER CHANG, KATHLEEN PIROLLO, ANTONINA RAIT
  • Publication number: 20030050254
    Abstract: A subject of the invention is the compounds of formula 1
    Type: Application
    Filed: July 2, 2002
    Publication date: March 13, 2003
    Applicant: Hoechst Marion Roussel
    Inventor: Alexis Denis
  • Publication number: 20020161030
    Abstract: The following products:
    Type: Application
    Filed: January 16, 2002
    Publication date: October 31, 2002
    Applicant: Hoechst Marion Roussel
    Inventors: Pierre Deprez, Jacques Dumas, Jacques Guillaume
  • Patent number: 6455505
    Abstract: A subject of the invention is, as new chemical products, the compounds of formula (I) in which X represents a hydrogen atom or a halogen atom and Z represents a hydrogen atom or the remainder of an acid as well as their addition salts with acids. The compounds of formula (I) have antibiotic properties.
    Type: Grant
    Filed: November 3, 1999
    Date of Patent: September 24, 2002
    Assignee: Hoechst Marion Roussel
    Inventors: Constantin Agouridas, Alexis Denis, Claude Fromentin
  • Patent number: 6437157
    Abstract: A compound selected from the group consisting of a compound of the formula wherein R1 and R2 are individually selected from the group consisting of alkyl of 1 to 12 carbon atoms and aralkyl of 7 to 15 carbon atoms or taken together form a saturated heterocycle of 5 to 6 ring members optionally having a second ring heteroatom selected from the group consisting of sulfur, oxygen and nitrogen, R3 is an &agr;-alkyl of 1 to 8 carbon atoms, n is an integer from 2 to 15, R4 is alkyl of 1 to 12 carbon atoms, R5 is selected from the group consisting of hydrogen, alkyl of 1 to 12 carbon atoms and acyl of an organic carboxylic acid of up to 12 carbon atoms and the wavy lines indicate that the 17- and 20-asymmetrical centers are independent of the absolute R and S configurations and their non-toxic, pharmaceutically acceptable acid addition salts useful for controlling fertility in male warm-blooded animals.
    Type: Grant
    Filed: March 13, 1995
    Date of Patent: August 20, 2002
    Assignee: Hoechst Marion Roussel
    Inventors: Armelle Bonfils, Daniel Philibert
  • Publication number: 20020045583
    Abstract: Substituted benzothiepine 1,1-dioxide derivatives of formula I: 1
    Type: Application
    Filed: February 2, 2001
    Publication date: April 18, 2002
    Applicant: Hoechst Marion Roussel Deutschland
    Inventors: Wendelin Frick, Alfons Enhsen, Heiner Glombik, Hubert Heuer
  • Publication number: 20020042381
    Abstract: Substituted propanolamine derivatives, their pharmaceutically tolerated salts and physiologically functional derivatives thereof are described.
    Type: Application
    Filed: April 13, 2001
    Publication date: April 11, 2002
    Applicant: Hoechst Marion Roussel Deutschland GmbH
    Inventors: Wendelin Frick, Reinhard Kirsch, Heiner Glombik, Werner Krammer, Hans-Ludwig Schafer
  • Publication number: 20020028781
    Abstract: A subject of the invention is, as new chemical products, the compounds of formula (I) 1
    Type: Application
    Filed: December 11, 2000
    Publication date: March 7, 2002
    Applicant: Hoechst Marion Roussel
    Inventors: Constantin Agouridas, Alexis Denis, Claude Fromentin
  • Publication number: 20020004601
    Abstract: Novel spiro[cyclopent[b]indole-piperidines], intermediates and processes for the preparation thereof, and methods of relieving memory dysfunction and treating depression utilizing the spiro[cyclopent[b]indole-piperidines] and intermediates, or compositions thereof are disclosed.
    Type: Application
    Filed: January 24, 2001
    Publication date: January 10, 2002
    Applicant: Hoechst Marion Roussel, Inc.
    Inventors: Mark G. Palermo, Gerard J. O'Malley
  • Publication number: 20020002155
    Abstract: The subject of the invention is the products of formula (I): 1
    Type: Application
    Filed: June 25, 2001
    Publication date: January 3, 2002
    Applicant: Hoechst Marion Roussel
    Inventors: Neerja Bhatnagar, Andre Claussner, Christian Marchandeau, Michele Resche Rigon, Jean-Georges Teutsch
  • Patent number: 6328963
    Abstract: A mouse anti-human MP52 monoclonal antibody which binds to dimeric human MP52 but not to monomeric human MP52. This mouse monoclonal antibody comprising IgG and having a high specificity can be obtained by sensitizing mice with human MP52 (CHO-MP52) produced in CHO cells and human MP52 (rhMP52) produced in escherichia coli. This antibody is useful in, for example, purifying or assaying human MP52 produced b genetic engineering techniques.
    Type: Grant
    Filed: December 23, 1998
    Date of Patent: December 11, 2001
    Assignee: Hoechst Marion Roussel
    Inventors: Hiroshi Kitagawa, Tomofumi Jitsukawa, Hiraku Nakagawa, Sachiko Yanagisawa
  • Publication number: 20010039268
    Abstract: A subject of the invention is the compounds of formula (I): 1
    Type: Application
    Filed: December 8, 2000
    Publication date: November 8, 2001
    Applicant: Hoechst Marion Roussel
    Inventors: Yamina Bouali, Francois Nique, Jean-Georges Teutsch, Patrick Van De Velde
  • Patent number: 6313305
    Abstract: A compound having the formula selected from the group consisting of wherein either R3p and R4p are identical and selected from the group consisting of —OH, protected —OH and acyloxy of 1 to 8 carbon atoms, R2p is selected from the group consisting of —CN, —F, Br and I and R1p and R5p are hydrogen or R5p is —F and R1p and R2p are hydrogen or R1p and R2p are F and R5p is hydrogen, or R4p and R5p are identical and selected from the group consisting of —OH, protected —OH and acyloxy of 1 to 8 carbon atoms, R3p is selected from the group consisting of F and —CN and R1p and R2p are hydrogen, R8 is hydrogen or an amine protective group and R10 is the remainder in which the hydroxy or amino are protected wherein R′1 is selected from the group consisting of alkyl of 1 to 4 carbon atoms, —CN, carboxy and alkoxy carbonyl of 1 to 4 carbon atoms.
    Type: Grant
    Filed: July 21, 1997
    Date of Patent: November 6, 2001
    Assignee: Hoechst Marion Roussel
    Inventors: Jozsef Aszodi, Jean-Francois Chantot, Patrick Fauveau, Solange Gouin d'Ambrieres, Daniel Humbert, Christophe Dini
  • Publication number: 20010012630
    Abstract: A subject of the invention is a modified yeast strain in which the acetyl-CoA pregnenolone acetyltransferase (APAT) activity is eliminated by altering the gene coding for this activity with resultant stabilization of 3&bgr;-hydroxysteroids.
    Type: Application
    Filed: March 1, 2001
    Publication date: August 9, 2001
    Applicant: Hoechst Marion Roussel
    Inventors: Tilman Achstetter, Gilles Cauet, Eric Degryse
  • Patent number: 6268520
    Abstract: Novel tricyclic compounds of formula I as defined in the specification, a process for their preparation and their use for the preparation of optically active or racemic colchicine and thiocolchicine derivatives.
    Type: Grant
    Filed: April 5, 1999
    Date of Patent: July 31, 2001
    Assignee: Hoechst Marion Roussel
    Inventors: Francis Brion, Bernadette Chappert, Christian Diolez, Christian Marie, Alain Mazurie, Michel Middendorp, Didier Pronine, Edmond Toromanoff